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ERM (ezrin/radixin/moesin) proteins are organizers of apical actin cortical layer in general. We previously reported that the knockout of
radixin resulted in Rdx−/− mice with displacement/loss of the canalicular transporter Mrp2, giving rise to Dubin–Johnson syndrome-like
conjugated hyperbilirubinemia in the mixed genetic background (C57BL/6-129/Sv) (Kikuchi, et al. (2002) Nature Genetics 31, 320–325).
However, when these mice were kept under mixed genetic background for years (late mixed backgrounds; LMB), the conjugated
hyperbilirubinemia gradually became inconspicuous, while evidence of liver injury increased. We examined the effect of genetic background by
backcrossing LMB Rdx−/− mice to C57BL/6 and 129/Sv wild type mice with the result that the Rdx−/− congenic mice regained
hyperbilirubinemia with reduced hepatocellular damage. As revealed by immunofluorescence and western blots, the localization/expression of
apical transporters, Mrp2, CD26, P-gps, and Bsep were not influenced by backcrossing, though those of a basolateral transporter, Mrp3, were
strikingly increased by backcrossing.
© 2006 Elsevier B.V. All rights reserved.Keywords: ERM; Mrp2; Mrp3; Hyperbilirubinemia; Genetic background1. Introduction
Basolateral and apical transport systems in the hepatocyte
perform the essential function of preventing intracellular
accumulation of potentially toxic endo- and xeno-biotic
substances. A deficiency or impairment of specific apical
transporters injures liver function in animal models of
cholestasis and in patients with cholestatic liver diseases [1–7].
Cholestasis reportedly induces adaptive or compensatoryAbbreviations: ERM, ezrin/radixin/moesin; mAb, monoclonal antibody;
pAb, polyclonal antibody; Mrp, multidrug resistance protein; Rdx, radixin;
Bsep, bile salt export pump; P-gps, P-glycoprotein; EMB, early mixed
background; LMB, late mixed background
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doi:10.1016/j.bbadis.2006.11.005changes in the localization/expression of hepatocellular efflux
pumps to decrease the cytoplasmic accumulation of potentially
toxic biliary constituents. A recently explored facet in the
functional regulation of hepatocyte transporters has been the
role of cytoskeletal components. At the secretory pole of
hepatocytes, the submembranous area is enriched in actin
filaments, which integrate the functional system of transporters
as well as facilitate the contraction of bile canaliculi [8].
ERM (ezrin/radixin/moesin) family proteins serve to
crosslink actin filaments and plasma membranes [9,10].
While functionally similar, their tissue and cellular localization
is distinct [11–13]. Radixin is the dominant ERM protein in
hepatocytes and is concentrated at the bile canalicular
membrane. We reported previously that radixin-deficient
(Rdx−/−) mice of 129/Sv×C57BL/6 mixed background
(designated here as to early mixed background; EMB) showed
conjugated hyperbilirubinemia with delocalization of Mrp2
Fig. 1. Hyperbilirubinemia in Rdx−/− and Rdx+/+ mice of different genetic backgrounds. (A) Serum concentrations of total bilirubin (T-bil) and direct/conjugated
bilirubin (D-bil) in wild type (+/+) and radixin deficient (−/−) mice at 4–12 weeks old (n=10–15) on different genetic backgrounds. C57BL/6 and 129/Sv congenic
mice (b, c), but not mice with the late mixed background (C57BL/6×129/Sv) (a), exhibited progressive hyperbilirubinemia. The levels of serum bilirubin in Rdx−/−
mice with late mixed background (LMB) were normal. Values are presented as means±SD. (B) Serum liver enzymes in Rdx−/−mice on different genetic backgrounds.
Serum liver enzymes were measured in serum from 12–16 week old mice of each genetic background. AST: aspartate aminotransferase, ALT: alanine
aminotransferase, AP: alkaline phosphatase. The results indicated that late mixed background mice without hyperbilirubinemia have more severe liver injury compared
with C57BL/6 and 129/Sv congenic background mice with hyperbilirubinemia. (C) Histopathological analysis of radixin deficient mice liver. Radixin deficient mice
liver without hyperbilirubinemia showed marked necrosis (a, b). Radixin deficient mice that were backcrossed into 129/Sv regained hyperbilirubinemia, but this strain
did not show hepatic injury (c, d). Bar, 100 μm (a, c); 20 μm (b, d).
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generations, late mixed backgrounds; LMB), the serum
bilirubin gradually decreased to the normal level, suggesting
an influence of genetic backgrounds on the level of serum
bilirubin in these mice. To explore this possibility, we
backcrossed the Rdx−/− mice into C57BL/6 and 129/Sv wild
type mice, respectively, assessing serum bilirubin levels as
well as the expression and localization of several transporters
including apical Mrp2, Bsep, P-gps, and basolateral Mrp3.
The results obtained suggested that the localization/expression
of apical transporters are independent of the genetic
background. In contrast, the localization/expression of the
basolateral Mrp3 is dependent on the genetic background, thus
determining the degree of the intrahepatic levels and the blood
levels of bilirubin and the cytotoxic endo- and xeno-biotic
substances.The regulation mechanism of the localization/expression of
the basolateral Mrp3 in liver is considered from various angles,
such as transcription and drug response. Here, the Rdx−/− mice
have provided a model system in the respect of the influence of
the impaired integration of apical bile canalicular transporters,
such as Mrp2, etc., on basolateral Mrp3. The genetic
background-dependent regulation of localization/expression of
basolateral Mrp3 may shedding light on the difference among
the patients of cholestasis in the level of hyperbilirubinemia and
hepatic injury.
2. Materials and methods
2.1. Animals
The previously generated radixin-deficient (Rdx−/−) mice were backcrossed into
C57BL/6 and 129/Svwild-typemice, respectively, throughmore than 8 generations.
300 K. Fukumoto et al. / Biochimica et Biophysica Acta 1772 (2007) 298–306All experiments were carried out in accordance with guidelines established by the
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2.2. Antibodies
We previously raised and characterized rat anti-radixin mAb [11]. Rat anti-
ZO-1 mAb was raised in this study, using GST-fused forms of the C-terminal
domain as an antigen. Rabbit anti-Mrp2 pAb (EAG15) [14] and guinea pig anti-
Mrp3 pAb (NL1) [15] were provided by Dr. D. Keppler. Mouse anti-P-gps mAb
(C219, Alexis Biochemicals, San Diego, CA), rabbit anti-ZO-1 pAb (ZYMED
Laboratories, San Francisco, CA), rat anti-ZO-1 mAb (CHEMICON, Temecula,
CA) and rat anti-CD26 mAb (BD Pharmingen, San Jose, CA) were purchased.
Rabbit anti-Bsep pAbs were kindly provided by Dr. B. Stieger and I.M.Arias
[16,17].
2.3. Immunofluorescence microscopy
The liver was removed from Rdx+/+ and Rdx−/− mice, cut into small pieces,
and frozen in liquid nitrogen. Frozen sections were cut on a cryostat, mounted
onto cover glasses, air-dried and fixed with 95% ethanol for 15 min at 4 °C
followed by 100% acetone for 1 min at room temperature. A pair of frozen
sections from the Rdx+/+ and Rdx−/− liver were placed on the same cover glass
and processed for double staining with the appropriate antibodies. Fluorescence
images were obtained with Delta Vision® (Applied Precision, WA) and
Axioplan2 (Plan Apochromat; Carl Zeiss Micro Imaging, Inc., NY).
2.4. Immunofluorescence microscopy and quantitative analysis
Samples were double stained with anti-radixin/anti-ZO-1, anti-Mrp2/anti-
ZO-1, anti-Bsep/anti-P-gps, anti-Bsep/anti-CD26, or anti-Mrp3/anti-ZO-1
antibodies. For quantification, relative intensities were determined and
calculated as previously described [18].
2.5. Immunoblotting
The liver was taken from Rdx+/+ and Rdx−/− mice and homogenized in SDS
sample buffer (50 mM Tris–HCl (pH 6.8), 2% SDS, 20% glycerol, 2% 2-
mercaptoethanol and 0.01% bromophenol blue). Total lysate (100 μg) was
separated by SDS-PAGE without boiling, and electrophoretically transferred
from gels to nitrocellulose membranes for immunoblotting. Immune complexes
were detected using horseradish-conjugated goat anti-rabbit or sheep anti-mouse
IgG fragments (dilution, 1:1000; Dako, Glastrup, Denmark) and the ECL
Western blotting detection system (Amersham, Buckinghamshire, UK). We
quantified the individual immunoblotted bands by comparing their intensities,
with those of serially-diluted reference standards for five separate combinations
of Rdx+/+ and Rdx−/− mice.3. Results
3.1. Genetic background-dependent hyperbilirubinemia and
hepatic injury in Rdx−/− mice
As previously reported, Rdx−/− mice of C57BL/6×129/Sv
mixed background were hyperbilirubinemic up to 8 generationsFig. 2. Genetic background-independent decrease of Mrp2 from apical bile canalicu
sections of the livers of wild type (Rdx+/+) and radixin deficient mice (Rdx−/−) with th
stained for Mrp2 and ZO-1. The patterns and intensities of bile canalicular ZO-1 stain
intensities of Mrp2 staining were significantly decreased in Rdx−/− mice of all
immunofluorescence intensities of Mrp2 and ZO-1 deduced from semi-quantitativ
canalicular area in Rdx−/− hepatocytes were decreased down to ∼55, ∼40, and ∼49
backgrounds, respectively. (C) Amounts of Mrp2 in livers of Rdx+/+ and Rdx−/− mice
liver protein from Rdx+/+ and Rdx−/− mice was loaded. Representative data were obta
and Rdx−/− mice. Bar, 20 μm.(referred as to the early mixed background; EMB) without
prominent hepatic injury. However, after 8 generations (late
mixed background; LMB), most Rdx−/− mice exhibited a
normal serum bilirubin (Fig. 1). At the same time, they
developed elevated serum levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and alkaline phospha-
tase (AP) and evidence of prominent hepatic injury (Fig. 1). To
explore the role of genetic background, we backcrossed Rdx+/−
mice of LMB with C57BL/6 and 129/Sv wild-type mice to
establish congenic Rdx−/− mice. As this backcrossing pro-
ceeded, the concentration of bilirubin in serum of Rdx−/− mice
increased progressively. After six generations of backcrossing, a
significant increase in total and direct (conjugated) bilirubin
levels was detected in the serum of both C57BL/6 and 129/Sv
congenic Rdx−/− mice (Fig. 1), though the hepatic injury is not
prominent (Fig. 1). We proceeded to examine the possibility that
changes in transporter expression were responsible for the
reappearance of the jaundiced phenotype.
3.2. Decrease in Mrp2 in the bile canalicular membrane of
Rdx−/− liver which is independent of genetic background
Mrp2 is a major ABC transporter which excretes bilirubin
from hepatocytes into bile canaliculi. We showed previously
that in Rdx−/− mice of EMB, Mrp2 is delocalized from the
canalicular membrane. We re-examined Mrp2 expression and
localization in Rdx+/+ and Rdx−/− mice of LMB, congenic
C57BL/6 and 129/Sv backgrounds using semi-quantitative
immunofluorescence microscopy. The levels of Mrp2 around
apical areas in Rdx−/− hepatocytes were significantly decreased
down to ∼55, ∼40, and ∼50% of those in Rdx+/+ hepatocytes
of LMB, and congenic C57BL/6 and 129/Sv backgrounds,
respectively (Fig. 2). This result was confirmed by immuno-
blotting (Fig. 2). Therefore, we conclude that a deficiency of
radixin consistently reduces Mrp2 expression at the bile
canalicular membrane.
3.3. Genetic background-independent decrease of expression of
Bsep, P-gps and CD26 in Rdx−/− liver
Bile canalicular apical transporters include Bsep and P-gps.
We examined expression of these transporters as well as the level
of CD26 (Dipeptidyl peptidase IV; DP-IV or CD26 ), an apical
marker, in Rdx+/+ and Rdx−/− mice of late mixed, congenic
C57BL/6, and congenic 129/Sv backgrounds. By semi-quanti-
tative immunofluorescence microscopy and immunoblotting,
the mean Rdx−/−/Rdx+/+ ratios for Bsep, P-gps, and CD26 were
around 70–80%, 70–80%, and 80–100%, respectively, in alllar membranes in Rdx−/− mice. (A) Immunofluorescence micrographs of frozen
e late mixed, congenic C57BL/6 or congenic 129/Sv genetic background, double
ing were very similar between the liver of Rdx+/+ and Rdx−/− mice, whereas the
genetic backgrounds examined. (B) Rdx−/−/Rdx+/+ ratios of bile canalicular
e immunofluorescence micrographs. The amounts of Mrp2 around apical bile
% of those in Rdx+/+ hepatocytes on LMB, and congenic C57BL/6 and 129/Sv
detected by western blotting with a pAb against Mrp2. In each lane, 100 μg of
ined from independent immunoblotting for five separate combinations of Rdx+/+
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ters and markers are not likely responsible for strain-related
variation in the Rdx−/− phenotype (Fig. 3). The Rdx−/−/Rdx+/+
ratios for Bsep, P-gps, and CD26 obtained by immunoblotting
(Fig. 3) were almost consistent with the results obtained by semi-
quantitative immunofluorescence microscopy, though some
discrepancies were recognized mainly due to the cytoplasmic
distribution of these apical transporters and markers. These
findings indicated that the normal level of bilirubin in LMB
Rdx−/− mice cannot be explained by possible changes in the
expression/localization of apically-localized membrane proteins
such as Mrp2, Bsep, P-gps and CD26.
3.4. Genetic background-dependent up-regulation of
hepatocellular Mrp3 in Rdx−/− mice with hyperbilirubinemia
The Mrp3 signal was very weak in the basolateral
membranes of hepatocytes in Rdx+/+ wild type mice on all
genetic backgrounds examined (Fig. 4). In Rdx−/− mice of EMB
with hyperbilirubinemia, the Mrp3 signal was increased,
whereas it was decreased in Rdx−/− mice of LMB without
hyperbilirubinemia. In Rdx−/− mice of the congenic C57BL/6
and 129/Sv backgrounds with hyperbilirubinemia, Mrp3
expression was remarkably up-regulated at the basolateral
membranes (Fig. 4). Semi-quantitative immunofluorescence
microscopy revealed that the Rdx−/−/Rdx+/+ ratios of Mrp3 in
congenic C57BL/6 and 129/Sv mice were∼310% and∼260%,
respectively, while the value in LMB mice was ∼90% (Fig. 4).
Immunoblotting analyses revealed that the total protein levels of
Mrp3 were significantly increased in Rdx−/− mice as compared
to Rdx+/+ mice of the congenic C57BL/6 and 129/Sv
backgrounds, but not of LMB (Fig. 4). These findings
suggested that Rdx−/− mice with hyperbilirubinemia expressed
low Mrp2 at apical membrane and high Mrp3 at basolateral
membranes and thus the hepatic injury was decreased as
compared to the severe hepatic injury of Rdx−/− mice of LMB
without hyperbilirubinemia due to low expressions of Mrp2 and
Mrp3.
4. Discussion
Mrp2 mediates ATP-dependent multispecific organ-anion
transport (e.g., bilirubin diglucuronide, sulfates, glutamine
conjugates) into bile, which plays an important role in the
excretion of glucuronide conjugated bilirubin from apical
surfaces of hepatocytes into bile canaliculi. The congenital
hyperbilirubinemia associated with Dubin–Johnson syndrome
is reportedly caused by mutations in Mrp2. Transport-
deficient (TR−) rats and Eisai hyperbilirubinemic rats thatFig. 3. Genetic background-independent changes in the amounts of Bsep, P-gps and
of the liver of wild type (Rdx+/+) and radixin deficient (Rdx−/−) mice with the la
backgrounds, double stained with pAbs against Bsep, mAbs against P-glycoproteins
and CD26 were moderately decreased in Rdx−/− mice as compared to Rdx+/+ mi
canalicular immunofluorescence intensities of Bsep, P-gps, and CD26 deduced fr
ratios were obtained for Bsep, P-gps, and CD26 on these genetic backgrounds. (C)
immunoblotting. In each lane, 100 μg of liver protein from Rdx+/+ and Rdx−
immunoblotting for five separate combinations of Rdx+/+ and Rdx−/− mice. Bar, 2lack Mrp2 or have a mutated form are animal models of
Dubin–Johnson syndrome [19,20]. Endotoxin lipopolysaccha-
ride and estradiol-17β-D-glucuronide induce endocytic inter-
nalization of Mrp2 and decreased bile flow and Mrp2
transport activity, which causes cholestasis in rats [21,22].
In our previous studies of Rdx−/− mice, we proposed that
conjugated hyperbilirubinemia was due to disruption of the
linkage between the actin cytoskeleton and the canalicular
membrane, with destabilization of Mrp2 [13]. The present
results provide evidence that compensatory expression of
another transporter, Mrp3, is an important determinant of
hyperbilirubinemia in the Rdx−/− mice.
There was no detectable difference in the expression or
localization of Mrp2 in Rdx−/− mice of all genetic background
examined. The change was detected in the basolateral level of
Mrp3, exceptionally among several transporters examined.
Mrp3 is a multispecific organ solute transporter and capable of
extruding bile salt conjugates from liver to sinusoidal space.
Reportedly, the expression is weak in normal liver but is highly
up-regulated on basolateral membrane of hepatocytes in
cholestasis [23]. Furthermore, along with up-regulation of
Mrp3 was diminished evidence of hepatocellular injury [24].
The data lead to the conclusion that increased expression and
activity of Mrp3 is a protective response to loss of canalicular
Mrp2. The obvious manifestation of this change is conjugated
hyperbilirubinemia. However, this pigment is not believed to be
inherently cytotoxic. Therefore, the more important adaptive
change may be increased export of other anions with significant
cytotoxic potential, either endogenous or dietary. Many phase II
metabolites are thought to be transported out of cells by
multidrug resistance proteins, which are up-regulated by
chemical activators of receptor-mediated pathways involved
in phase I drug metabolism, such as aryl hydrocarbon receptor
ligand and constitutive androstane receptor ligand, etc. [25]. In
cellular models, ectopic expression of Mrp3 confers resistance
to etoposide and methotrexate, consistent with the hypothesis
that the pump is a resistance factor to protect normal tissues
from chemotherapeutic agents with different substrate selectiv-
ities from Mrp1 and Mrp2 [26].
In the present study, we have shown the adaptive up-
regulation of Mrp3 in cholestasis in Rdx−/− mice. Similar
adaptive changes of Mrp3 have been reported in experimental
cholestasis. Mrp3 is increased in the Eisai hyperbilirubinemic
rat, which has a deficiency of Mrp2 [20]. Also, bile duct
ligation in rats has reportedly raised the protein levels of
Mrp3 in basolateral membranes of hepatocytes [3,4]. In this
connection, Mrp3-null mice accumulate increased levels of
hepatic bile acids with reduced serum bilirubin glucuronide
after bile duct ligation [27] and also show alteredCD26 in Rdx−/− liver. (A) Immunofluorescence micrographs of frozen sections
te mixed background (LMB), and the congenic C57BL/6 and 129/Sv genetic
(P-gps) and CD26. The intensities of bile canalicular staining for Bsep, P-gps,
ce but did not differ by genetic background. (B) Rdx−/−/Rdx+/+ ratios of bile
om semi-quantitative immunofluorescence microscopy. Similar Rdx−/−/Rdx+/+
Amounts of Bsep and CD26 in livers of Rdx+/+ and Rdx−/− mice detected by
/− mice was loaded. Representative data were obtained from independent
0 μm.
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Fig. 4. Genetic background-dependent changes in the amount of Mrp3 in liver of Rdx−/−mice. (A) Immunofluorescence micrographs of frozen sections of liver of wild
type (Rdx+/+) and radixin deficient (Rdx−/−) mice with the late mixed background, and congenic C57BL/6 and 129/Sv genetic backgrounds, double stained for Mrp3
and ZO-1. Basolateral Mrp3 staining was nearly undetectable in Rdx+/+ liver regardless of genetic background. In Rdx−/− liver of late mixed background, Mrp3-
staining was also very weak. In contrast, it was markedly enhanced on the congenic C57BL/6 and 129/Sv genetic backgrounds. (B) Rdx−/−/Rdx+/+ ratios of basolateral
immunofluorescence intensities of Mrp3 deduced from semi-quantitative immunofluorescence microscopy. The basolateral levels of Mrp3 were markedly increased in
Rdx−/− liver as compared to Rdx+/+ liver on the congenic C57BL/6 and 129/Sv backgrounds, but were unchanged on the late mixed background. (C) Amounts of Mrp3
in the liver of Rdx+/+ and Rdx−/−mice detected by western blotting. In each lane, 100 μg of liver protein of Rdx+/+ and Rdx−/−mice was loaded. The amounts of Mrp3
were greatly increased in Rdx−/− liver on the congenic C57BL/6 and 129/Sv backgrounds, but not on the late mixed background. Representative data were obtained
from independent immunoblotting for five separate combinations of Rdx+/+ and Rdx−/− mice. Bar, 20 μm.
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and acetaminophen [28,29]. From the standpoint of regulation
of Mrp3 expression, Mrp3 has been shown to be up-regulated
by bile acids, possibly by linking to signal transduction and
transcriptional pathways that govern bile acid homeostatic
mechanisms, the detailed mechanisms of which is though
unknown [30,31]. In Sprague–Dawley rats the regulation of
Mrp3 appears to be post-transcriptional [19], although this
was questioned in studies of human inflammatory cholestasis,
primary biliary cirrhosis, and chronic hepatitis C [7,23,32],
remaining to be elucidated in future.
In Dubin–Johnson syndrome, identified genetically or by
urine coproporphyrin analysis, serum bilirubin varies over abroad range, from normal to markedly elevated. There are
contradictive reports about expression of Mrp3 and hepatic
injury in Mrp2 deficient mice [33,34]. Our findings suggest that
one reason for variation is the level of export traffic via Mrp3.
Similar variation is seen in obstructive jaundice. Some patients
do not have high levels of conjugated bilirubin despite complete
obstruction of the biliary system [6]. On the other hand, it has
been reported that Mrp3 expression is increased in primary
biliary cirrhosis [23].
In conclusion, disruption of Mrp2 on the canalicular
membrane in Rdx−/− mice leads to a variable compensatory
increase in Mrp3, depending on the genetic background manner.
While its molecular regulation remains to be elucidated, the
305K. Fukumoto et al. / Biochimica et Biophysica Acta 1772 (2007) 298–306change appears to be central to generating the signature
phenotype, hyperbilirubinemia, of these mice. Up-regulation
of Mrp3 prevents hepatotoxicity, presumably by excreting
other, more deleterious anions. Thus, Mrp3 is considered to be a
possible molecular target for cholestasis.
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